CRMD Logo

CorMedix Inc. (CRMD) 

NASDAQ
Market Cap
$621.28M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
258 of 776
Rank in Industry
150 of 433

Largest Insider Buys in Sector

CRMD Stock Price History Chart

CRMD Stock Performance

About CorMedix Inc.

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as …

Insider Activity of CorMedix Inc.

Over the last 12 months, insiders at CorMedix Inc. have bought $74,968 and sold $0 worth of CorMedix Inc. stock.

On average, over the past 5 years, insiders at CorMedix Inc. have bought $257,961 and sold $55,394 worth of stock each year.

Highest buying activity among insiders over the last 12 months: Todisco Joseph (Chief Executive Officer) — $101,436. DUNTON ALAN W (director) — $40,500. Mistry Erin (Chief Commercial Officer) — $4,000.

The last purchase of 13,561 shares for transaction amount of $50,718 was made by Todisco Joseph (Chief Executive Officer) on 2024‑03‑13.

List of Insider Buy and Sell Transactions, CorMedix Inc.

2024-03-13PurchaseChief Executive Officer
13,561
0.024%
$3.74$50,718+34.78%
2023-12-15Purchasedirector
3,000
0.0055%
$3.30$9,900+43.20%
2023-12-14Purchasedirector
3,000
0.0055%
$3.45$10,350+37.10%
2023-11-17PurchaseChief Commercial Officer
1,000
0.0018%
$4.00$4,000+11.08%
2023-09-08PurchaseChief Executive Officer
10,000
0.0183%
$3.71$37,100+1.76%
2023-05-18Purchasedirector
6,000
0.0139%
$4.54$27,258-14.19%
2023-05-17PurchaseChief Executive Officer
5,000
0.0119%
$4.58$22,900-13.01%
2023-05-17Purchasedirector
10,000
0.0227%
$4.37$43,735-13.01%
2023-05-17Purchasedirector
10,000
0.0241%
$4.65$46,500-13.01%
2023-05-17Purchasedirector
3,000
0.0067%
$4.33$12,980-13.01%
2022-11-15PurchaseChief Executive Officer
20,000
0.0514%
$3.82$76,400+11.79%
2022-08-24PurchaseChief Executive Officer
4,700
0.0114%
$3.92$18,424+4.58%
2022-05-17Purchase
5,000
0.0124%
$3.78$18,900+3.40%
2022-05-16PurchaseChief Executive Officer
10,000
0.0235%
$3.38$33,800+8.86%
2021-12-06PurchaseInterim CEO and CFO
2,000
0.0052%
$4.50$9,000-13.93%
2021-11-17PurchaseInterim CEO and CFO
1,000
0.0027%
$5.07$5,070-20.71%
2021-11-16Purchasedirector
10,000
0.0262%
$5.14$51,400-22.60%
2021-05-21SaleEVP, Head of Clinical Ops
8,000
0.0212%
$6.92$55,394-28.17%
2021-05-17Purchasedirector
15,000
0.0382%
$6.03$90,477-20.42%
2020-09-04Purchasedirector
5,715
0.0193%
$3.99$22,816+86.25%

Insider Historical Profitability

12.22%
Todisco JosephChief Executive Officer
352839
0.5815%
$10.2460+1.12%
DUNTON ALAN Wdirector
15250
0.0251%
$10.2440+37.56%
Mistry ErinChief Commercial Officer
4900
0.0081%
$10.2410
Gelbfish Gary A.director
2101121
3.4628%
$10.2420<0.0001%
TELLEZ CORA Mdirector
182371
0.3006%
$10.24150<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
BlackRock$14.78M6.353.49M-0.59%-$87,772.24<0.0001
Nomura Holdings$12.51M5.372.95M+0.17%+$20,720.880.11
The Vanguard Group$12.42M5.332.93M+3.64%+$436,088.25<0.0001
Elliott Investment Management L P$6.57M2.821.55M0%+$00.07
Geode Capital Management$5.02M2.151.18M+2.1%+$103,315.71<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.